Close Menu
Home » Guardant Health Liquid Biopsy Test Gets Draft LCD for Most Advanced Solid Tumors

Guardant Health Liquid Biopsy Test Gets Draft LCD for Most Advanced Solid Tumors

Mar 28, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA has proposed coverage for Guardant Health's 73-gene Guardant360 liquid biopsy test in more than a dozen solid tumor types where biomarker information is needed to inform their treatment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Cleared the Committee

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

Hope, But Cost Worries

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

One Gene to Shape the Face

One gene regulates hundreds of others to influence facial development, according to New Scientist.

Nature Studies Review Resources for Single-Cell Analysis, Examine ALS Exomes, More

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.

Dec
11
Featured Webinar

Advances in Precision Oncology: Tertiary Analysis Software for Solid Tumor NGS

Sponsored by
Roche

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Molecular Diagnostics

  1. NCCN Updates Genetic Testing Guidelines for Assessing Breast, Ovarian, Pancreatic Cancer Risk

  2. FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray

  3. Ambry Genetics, Caris Life Sciences Partner on Cancer Genetic Testing

  4. Illumina, ArcherDx Expand Partnership on NGS IVD Tests

  5. Veracyte Exclusively Licenses NanoString Diagnostic Platform for Up to $60M

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.